Evidence map›Paper›PMID 38849500›Full record

ReviewHypertension research : official journal of the Japanese Society of Hypertension2024

Prescription and dispensing duration of medicines for hypertension and other chronic conditions: a review of international policies and evidence to inform the Australian setting.

Peder Af Geijerstam, Michael O Falster, John Chalmers, Andrew J McLachlan, Anthony Rodgers, Aletta E Schutte

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hypertension research : official journal of the Japanese Society of Hypertension, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Peder Af GeijerstamDepartment of Health, Medicine and Caring Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.ORCID 0000-0001-6038-5131
Michael O FalsterSchool of Population Health, University of New South Wales, Sydney, NSW, Australia.ORCID 0000-0001-6444-7272
John ChalmersThe George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.ORCID 0000-0002-9931-0580
Andrew J McLachlanSydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.ORCID 0000-0003-4674-0242
Anthony RodgersThe George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.ORCID 0000-0003-1282-1896
Aletta E SchutteThe George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia. a.schutte@unsw.edu.au.ORCID 0000-0001-9217-4937

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The duration of treatment for which a physician may prescribe a medicine, 'prescription duration', is often dispensed at the pharmacy on multiple occasions of shorter time periods, 'dispensing duration'. These durations vary significantly between and within countries. In Australia, the quantity of medication supplied at each dispensing has recently been extended from 30 to 60 days for a selection of medicines used for chronic health conditions, such as diabetes and hypertension. Dispensing durations vary between countries, with 30, 60 or 90 days being the most common-with 90 days aligning with the recommendation of the 2023 Global Report on Hypertension from the World Health Organization. The full impact of shorter vs longer prescription durations on health costs and outcomes is unknown, but current evidence suggests that 90-day dispensing could reduce costs and improve patient convenience and adherence. More rigorous research is needed.

Indexed as

Antihypertensive AgentsHypertensionAustraliaChronic DiseaseDrug PrescriptionsHealth PolicyHumansAntihypertensive AgentsDispensing durationHealth costsHealth outcomesMedication adherencePrescription duration

Identifiers

PMID38849500
PMCPMC11298406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.